An overview of key information from the analysis.
0
%
of overall spend on site specific cancer research is on rare and less common cancers
0
%
drop in cancer research funding during 2020/2021
0
%
of new cancers are rare or less common
0
%
55 of cancer deaths are due to a rare or less common cancer
£
0
m
combined spend for site specific rare and less common cancer research in 2021
0
/12
leading principal investigator institutions were also designated Experimental Cancer Medicine Centres (ECMCs)
0
%
organisations found the pandemic had a negative impact in funding cancer research in the financial year 2020/21
0
The number of Cancer52 member organisations whose data were used in the analysis
The Common Scientific Outline (CSO) was used to classify the data.
Rare and less common cancers are defined as any cancer other than the four most common cancers; lung, breast, bowel and prostate.*
*Cancer Incidence. Cancer Research UK. Available: https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk#heading-Zero.